Lista de obras -

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection

artículo científico publicado en 2009

An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy.

artículo científico publicado en 2013

Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection

artículo científico publicado en 2013

Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection

artículo científico publicado en 2016

Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.

artículo científico publicado en 2016

Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients

artículo científico publicado en 2014

Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy

artículo científico publicado en 2017

Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV.

artículo científico publicado en 2016

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden

artículo científico publicado en 2011

Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection

artículo científico publicado en 2014

Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study

artículo científico publicado en 2006

Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection

artículo científico publicado en 2013

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen

artículo científico publicado en 2004

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection

article

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy

artículo científico publicado en 2013

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection

artículo científico publicado en 2010

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy

artículo científico publicado en 2012

Cerebrospinal fluid viral load and intrathecal immune activation in individuals infected with different HIV-1 genetic subtypes

artículo científico publicado en 2008

Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection

artículo científico publicado en 2004

Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection

artículo científico publicado en 2002

Corrigendum to: "Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study" [EBioMedicine 3 (216) 135-140].

artículo científico publicado en 2016

Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers

scientific article published on 12 September 2006

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment

artículo científico publicado en 2010

Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance

artículo científico publicado en 2020

Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy

artículo científico publicado en 2007

No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).

artículo científico publicado en 2016

Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report

artículo científico publicado en 2006

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy

artículo científico publicado en 2008

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

artículo científico publicado en 2015

Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection

artículo científico publicado en 2014

Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study

artículo científico publicado en 2016

Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

artículo científico publicado en 2010

Lista de obras de

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection

An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy.

Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection

Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection

Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.

Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients

Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy

Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV.

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden

Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection

Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study

Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy

Cerebrospinal fluid viral load and intrathecal immune activation in individuals infected with different HIV-1 genetic subtypes

Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection

Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection

Corrigendum to: "Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study" [EBioMedicine 3 (216) 135-140].

Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment

Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance

Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy

No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).

Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection

Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study

Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.